- Dr. Gericke brings extensive experience in the research and development of radioligand therapies
- The appointment coincides with the launch of Ariceum International AG in Basel, Switzerland
BERLIN, February 1, 2023 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotechnology company developing radiopharmaceuticals for the diagnosis and targeted systemic radiation therapy of certain difficult-to-treat cancers, is pleased to announce the appointment of Germo Gericke, MD, to position of Medical Director Officer.
Germo joins Ariceum from Novartis, where he most recently served as Medical Director and Global Head of Research and Development at Advanced Accelerator Applications (AAA), a Novartis company specializing in the field of nuclear medicine. Germo will be based in the new subsidiary of Ariceum in Basel, Switzerland. Basel offers one of the largest talent pools Europe for the development and commercialization of innovative pharmaceutical products.
Manfred Rüdiger, PhD, CEO of Ariceum Therapeutics, said“I am delighted to welcome Germo to the Ariceum management team at a pivotal time in the company’s growth and clinical development. Germo brings with him a wealth of experience in the field of radiopharmaceutical therapy and this It’s a testament to the potential of Ariceum’s theranostic portfolio that someone of Germo’s caliber has chosen to join our team Germo will build and lead the clinical development and operations team for our new subsidiary in Basel.”
Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics, commented: “I am delighted to join Ariceum which focuses on systemic targeted radiotherapy. Ariceum is actively working on the development of innovative drugs for the diagnosis, monitoring and precision treatment of certain aggressive neuroendocrine cancers, such as small cell lung cancer (SCLC). These cancers have few treatment options and poor prognoses, so I look forward to contributing to Ariceum’s mission to improve the lives of those facing these very challenging diseases.”
Germo joins Ariceum from Advanced Accelerator Applications (AAA), a Novartis company developing targeted radioligands and precision imaging radioligands for oncology indications. As a member of the management team, he served as Medical Director and Director of Research and Development, building a global R&D organization for therapeutic radioligands. Prior to AAA, Germo served as Global Franchise Program Manager in Oncology Development and in strategic, commercial and general leadership roles with increasing responsibility across a range of therapeutic and geographic areas, after joining Novartis in 2001 after leaving McKinsey & Company. Germo studied medicine at the Charité University Hospital in Berlin and holds an MD from the University of Heidelberg.
Notes to Editors
About Ariceum Therapeutics
Ariceum Therapeutics (Ariceum) is a private, clinical-stage radiopharmaceutical company focused on the precision diagnosis and treatment of certain neuroendocrine cancers and other aggressive, difficult-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium were huge contributions to the search for cancer treatments. Ariceum’s primary targeted systemic radiopharmaceutical, 177Lu-satoreotide tetraxetan (“satoreotide”) is a somatostatin type 2 antagonist (SST2) receptor that is overexpressed in neuroendocrine tumors (NET), some aggressive cancers such as small cell lung cancer (SCLC), and childhood cancer, neuroblastoma, all of which have few treatment options and bad predictions. Satoreotide is being developed as a “theranostic” couple for the combined diagnosis and targeted radionuclide treatment of these tumours.
Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ariceum is headquartered in Berlinwith operations in Germany and Swiss and activities currently through Europe, North America and Australia.
Ariceum is led by a highly experienced management team and backed by specialist investors including EQT Life Sciences (formerly LSP), HealthCap and Pureos Bioventures. For more information, visit www.ariceum-therapeutics.com
SOURCE Ariceum Therapeutics